Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease

    Study Rationale: 
    Currently, there are no tools to predict whether someone is at risk of developing Parkinson’s disease or to diagnose the early stages of the disease before motor symptoms can be...

  • Target Advancement Program, 2020
    Determining the Ligase and DUB Landscape of Mitochondrial and Alpha-synuclein Turnover

    Study Rationale:        
    Research suggests that accumulation of faulty mitochondria (the “powerhouse” of the cell) or mutated forms of the protein alpha-synuclein in the brain contribute to the...

  • Alpha-Synuclein Imaging, 2020
    Optimization of Morphomer-Based Alpha-synuclein PET Tracers
    Ken Griffin Alpha-synuclein Imaging Competition Logo

    Study Rationale:
    The team at AC Immune has discovered a variety of compounds that can bind to a specific Parkinson’s disease-associated form of the protein alpha-synuclein. AC Immune has previously...

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    RT-QuIC Testing of Misfolded Alpha-synuclein in S4 Study Samples

    Study Rationale:
    The protein alpha-synuclein is vital to normal brain function. In Parkinson's disease, alpha-synuclein misfolds, forming aggregates, or clumps, that impair the ability of brain cells...

  • Therapeutic Pipeline Program, 2020
    Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients

    Study Rationale: 
    Clumps of the protein alpha-synuclein, called Lewy bodies, are a hallmark of Parkinson’s disease and a promising target for therapeutic development. Anle138b is a drug-like compound...

  • Research Grant, 2020
    UCLA-California PD Registry-EHR (UCE-PD) Demonstration Project

    Study Rationale:
    We want to improve the quality of data being collected by the California Parkinson’s Disease Registry (CPDR). The CPDR now requires all clinicians in the state of California to report...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.